Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study

Robert Chapman, John Crowley, Joel G. Lucas, Ben Lin Hom, Robert B. Livingston, Clarence B. Vaughn, Harry E. Hynes

Research output: Contribution to journalArticlepeer-review

Abstract

This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.

Original languageEnglish (US)
Pages (from-to)91-92
Number of pages2
JournalInvestigational New Drugs
Volume11
Issue number1
DOIs
StatePublished - Feb 1993

Keywords

  • cisplatin
  • mitogauzone
  • vinblastine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study'. Together they form a unique fingerprint.

Cite this